AbbVie (ABBV) 10-K2023 FY Annual report

Filed: 20 Feb 24, 12:45pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ADC, Aquipta, array, assembly, atrial, back, Bermuda, briefly, BRVO, buckbee, Camargo, CANOVA, cardiac, ceiling, Cerevel, characterized, CISSP, Clawback, cloud, CMS, COMMAND, Commissioner, compelling, competitor, composed, conjugate, corticosteroid, CRVO, cybersecurity, deciding, dexamethasone, disaster, DLBCL, DME, Donoghoe, dyskinesia, Elahere, endoscopic, enterprise, epcoritimab, epithelial, Epkinly, fallopian, fat, fibrillation, flagship, footnote, Fortune, FR, Hetero, HS, hyperkinesia, IMMpulse, ImmunoGen, incident, INSPIRE, Intelligence, intravitreal, involuntary, IRA, jennifer, kevin, LUMINOSITY, lutikizumab, McKinsey, meaningfully, median, MF, mirvetuximab, mood, navitoclax, NIST, nonsurgical, Occlusion, OECD, oedema, onset, Otezla, outpace, peritoneal, PFS, Pillar, platysma, pocket, pomalidomide, PomDex, postoperative, Produodopa, prominence, proximity, PsO, pump, quaggin, remission, Resubmission, retrospective, Roopal, ruxolitinib, satisfactory, scanning, SEQUENCE, serotype, shift, skin, Skinvive, slowly, solid, Spleen, Stelara, surgery, survival, susan, Symptom, tabletop, Tepkinly, Thakkar, threshold, toxin, trenibotulinumtoxinE, tube, unanimously, undertaken, undetected, Vein, VenDex, visual, vitiligo, voluntary, widespread, withheld

Removed: adjustment, advisory, Alvogen, appealed, augmentation, began, Biopharma, brian, Brook, Carrie, commercializing, confidence, Cook, creditable, Cruz, cycle, defendant, denied, durkin, Elaine, Eli, Elliott, existed, expanded, expanding, explore, filler, finalized, forma, franchise, fulfillment, HArmonyCa, internally, intervening, justice, lattice, lemzoparlimab, Lilly, locally, Luminera, MAA, monitored, monoclonal, Natco, operational, pain, Pine, predicted, prioritized, privately, pro, projection, racial, ranged, ratio, reclassification, reiterated, Santa, scale, separately, Shire, sNDA, soft, Sorg, spread, stream, Strom, surgical, technique, teen, twelve, unaudited, uninterrupted, wholly, XC

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABBV transcripts

ABBV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 31.2

Certification of Chief Financial Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Scott T. Reents, certify that:

1.I have reviewed this annual report on Form 10-K of AbbVie Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report;

4.AbbVie’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for AbbVie and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of AbbVie’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in AbbVie’s internal control over financial reporting that occurred during AbbVie’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie’s internal control over financial reporting; and

5.AbbVie’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie’s auditors and the audit committee of AbbVie’s board of directors:

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie’s internal control over financial reporting.


Date: February 20, 2024			/s/ Scott T. Reents
			Scott T. Reents, Executive Vice President, Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.